IN2012DN02993A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02993A IN2012DN02993A IN2993DEN2012A IN2012DN02993A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A IN 2993DEN2012 A IN2993DEN2012 A IN 2993DEN2012A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A
- Authority
- IN
- India
- Prior art keywords
- ebv
- provides
- present
- cell
- tcr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/05—Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention provides a T-cell receptor (TCR) which binds to a peptide from latent membrane protein 2 (LMP-2) from the Epstein Barr Virus (EBV) having the amino acid sequence CLGGLLTMV (SEQ ID No. 1) when presented by a major histocampatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a EBV-specific T-cell. The present invention also provides the use of EBV-specific T-cell for cellular immunotherapy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0917090.3A GB0917090D0 (en) | 2009-09-29 | 2009-09-29 | T-cell receptor |
PCT/GB2010/001821 WO2011039508A2 (en) | 2009-09-29 | 2010-09-28 | T-cell receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02993A true IN2012DN02993A (en) | 2015-07-31 |
Family
ID=41350560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2993DEN2012 IN2012DN02993A (en) | 2009-09-29 | 2010-09-28 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8889141B2 (en) |
EP (1) | EP2483294B1 (en) |
JP (2) | JP6180114B2 (en) |
KR (1) | KR101760277B1 (en) |
CN (1) | CN102695717B (en) |
AU (1) | AU2010302477B2 (en) |
ES (1) | ES2584541T3 (en) |
GB (1) | GB0917090D0 (en) |
IN (1) | IN2012DN02993A (en) |
WO (1) | WO2011039508A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ710810A (en) | 2011-04-08 | 2016-09-30 | Baylor College Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
EP3424947B1 (en) | 2011-10-28 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
WO2013088114A1 (en) | 2011-12-12 | 2013-06-20 | Cell Medica Limited | Process of expanding t cells |
WO2013119947A1 (en) | 2012-02-09 | 2013-08-15 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
WO2014042226A1 (en) | 2012-09-12 | 2014-03-20 | 株式会社癌免疫研究所 | Antigen-specific helper t-cell receptor genes |
AU2014290288B2 (en) | 2013-07-15 | 2018-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human papillomavirus 16 E6 T cell receptors |
GB201314404D0 (en) * | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
DK3149031T3 (en) * | 2014-05-29 | 2020-03-16 | Us Health | ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T-CELL RECEPTORS |
WO2015199618A1 (en) * | 2014-06-24 | 2015-12-30 | National University Of Singapore | Epstein-barr virus lmp2 specific antibody and uses thereof |
EP3212225A4 (en) | 2014-10-31 | 2018-10-17 | The Trustees of The University of Pennsylvania | Methods and compositions for modified t cells |
CN107001444B (en) * | 2014-12-17 | 2020-11-27 | 中国科学院广州生物医药与健康研究院 | T cell receptor for identifying EB virus short peptide |
EP3237374A4 (en) | 2014-12-23 | 2018-04-25 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
RS64540B1 (en) | 2015-04-06 | 2023-09-29 | Regeneron Pharma | Humanized t cell mediated immune responses in non-human animals |
CN104830793A (en) * | 2015-05-05 | 2015-08-12 | 杨光华 | DC cell based on LMP-1 antigen, targeting immune cell population, preparation method and applications thereof |
SG10202110887PA (en) * | 2015-06-09 | 2021-11-29 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
KR101794304B1 (en) | 2015-09-01 | 2017-11-06 | 가톨릭대학교 산학협력단 | EBV antigen specific T-cell receptor and use thereof |
JP6999941B2 (en) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | Identification of immunogenic antigens from pathogens and their correlation with clinical efficacy |
GB201520191D0 (en) * | 2015-11-16 | 2015-12-30 | Cancer Rec Tech Ltd | T-cell receptor and uses thereof |
CA3014515A1 (en) | 2016-02-26 | 2017-08-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
TW201825499A (en) * | 2016-09-19 | 2018-07-16 | 德商拜耳作物科學股份有限公司 | Fused bicyclic heterocycle derivatives as pesticides |
CN108218976B (en) * | 2016-12-09 | 2021-11-05 | 香雪生命科学技术(广东)有限公司 | Tumor antigen short peptide derived from LMP1 |
EP3666887A4 (en) | 2017-08-10 | 2021-09-01 | Good T Cells, Inc. | Method for activating t cells for cancer treatment |
SG11202101671PA (en) * | 2018-11-27 | 2021-03-30 | Univ Duke | Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers |
CN113423724B (en) * | 2018-12-27 | 2023-11-24 | 深圳华大生命科学研究院 | EBV epitope high affinity T cell receptor |
EP3786178A1 (en) | 2019-08-30 | 2021-03-03 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for ebv-derived antigens |
WO2021211455A1 (en) * | 2020-04-13 | 2021-10-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against lmp2 |
WO2021243695A1 (en) * | 2020-06-05 | 2021-12-09 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Tcr-t cell therapy targeting epstein-barr virus |
EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
CN113773378B (en) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T cell receptor and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101182531B (en) * | 2007-11-09 | 2010-06-02 | 暨南大学 | Recombination plasmid related with EB virus specificity TCR gene and method for constructing anti-EBV specific CTL |
-
2009
- 2009-09-29 GB GBGB0917090.3A patent/GB0917090D0/en not_active Ceased
-
2010
- 2010-09-28 AU AU2010302477A patent/AU2010302477B2/en not_active Ceased
- 2010-09-28 US US13/498,561 patent/US8889141B2/en not_active Expired - Fee Related
- 2010-09-28 JP JP2012531494A patent/JP6180114B2/en not_active Expired - Fee Related
- 2010-09-28 KR KR1020127009216A patent/KR101760277B1/en active IP Right Grant
- 2010-09-28 CN CN201080053971.2A patent/CN102695717B/en not_active Expired - Fee Related
- 2010-09-28 WO PCT/GB2010/001821 patent/WO2011039508A2/en active Application Filing
- 2010-09-28 EP EP10777061.2A patent/EP2483294B1/en not_active Not-in-force
- 2010-09-28 IN IN2993DEN2012 patent/IN2012DN02993A/en unknown
- 2010-09-28 ES ES10777061.2T patent/ES2584541T3/en active Active
-
2015
- 2015-11-09 JP JP2015219230A patent/JP2016047064A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN102695717B (en) | 2016-08-10 |
EP2483294B1 (en) | 2016-07-13 |
US20120244132A1 (en) | 2012-09-27 |
JP2016047064A (en) | 2016-04-07 |
ES2584541T3 (en) | 2016-09-28 |
EP2483294A2 (en) | 2012-08-08 |
US8889141B2 (en) | 2014-11-18 |
JP2013505734A (en) | 2013-02-21 |
AU2010302477B2 (en) | 2017-01-19 |
JP6180114B2 (en) | 2017-08-16 |
AU2010302477A1 (en) | 2012-04-19 |
KR20120074291A (en) | 2012-07-05 |
WO2011039508A2 (en) | 2011-04-07 |
GB0917090D0 (en) | 2009-11-11 |
KR101760277B1 (en) | 2017-07-21 |
WO2011039508A3 (en) | 2011-06-30 |
CN102695717A (en) | 2012-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02993A (en) | ||
MX350126B (en) | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof. | |
PH12016500272A1 (en) | T cell receptors | |
AU2017248122A1 (en) | T cell receptors | |
NZ610267A (en) | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use | |
MX2022005922A (en) | Prame tcr receptors and uses thereof. | |
GB201206559D0 (en) | Polypeptide | |
NZ598356A (en) | Antigenic tau peptides and uses thereof | |
HRP20240676T1 (en) | Fibronectin based scaffold domain proteins that bind to myostatin | |
WO2013151672A3 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
NZ704192A (en) | Cell-penetrating peptides and uses therof | |
NZ602119A (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
JP2008543314A5 (en) | ||
NZ706884A (en) | Fc gamma receptor iib variants | |
MX2015003310A (en) | Novel il-17a binding molecules and medical uses thereof. | |
JP2017514522A5 (en) | ||
NZ705899A (en) | Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof | |
WO2016130628A8 (en) | Griffithsin mutants | |
NZ586074A (en) | LCLRP peptides, constructs and uses thereof | |
NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
MX2011007963A (en) | Neil3 peptides and vaccines including the same. | |
MX2009007261A (en) | Foxp3 peptide vaccine. | |
Koh et al. | Degradation-resistant protein domains limit host cell processing and immune detection of mycobacteria | |
NZ603611A (en) | Insulin-like growth factor 1 receptor binding peptides | |
NZ592461A (en) | Rab6kifl/kif20a epitope peptide and vaccines containing the same |